K2 Principal Fund L.P. Takes $284,000 Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

K2 Principal Fund L.P. purchased a new position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) in the second quarter, HoldingsChannel reports. The institutional investor purchased 489,158 shares of the company’s stock, valued at approximately $284,000.

Other large investors have also recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc raised its holdings in shares of X4 Pharmaceuticals by 4.6% during the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after buying an additional 111,032 shares during the period. XTX Topco Ltd acquired a new stake in X4 Pharmaceuticals in the second quarter valued at approximately $65,000. Rhumbline Advisers raised its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares during the period. Bank of New York Mellon Corp lifted its position in shares of X4 Pharmaceuticals by 39.7% during the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after purchasing an additional 133,398 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after purchasing an additional 12,514 shares during the period. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

XFOR has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $5.00 price target on shares of X4 Pharmaceuticals in a research note on Friday, May 31st. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of X4 Pharmaceuticals in a research report on Friday, June 28th.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $0.71 on Tuesday. The company has a market capitalization of $118.58 million, a P/E ratio of -1.01 and a beta of 0.36. The firm has a 50 day simple moving average of $0.71 and a 200-day simple moving average of $0.92. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79. X4 Pharmaceuticals, Inc. has a twelve month low of $0.53 and a twelve month high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.03). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $52.98 million. During the same period in the prior year, the firm earned ($0.33) earnings per share. On average, equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.

X4 Pharmaceuticals Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.